patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_457873 | REC_0009301 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 3.2 | 67 | male | 0 | 3 | 5.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.7 | false | MSS | 2026-03-15T05:35:59.150822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359147 | REC_0009302 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 10.7 | 59 | male | 1 | 9 | 4.9 | 5 | osimertinib 80 mg daily | 5.3 | true | MSI-H | 2026-03-15T05:35:59.151065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117251 | REC_0009303 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.6 | 80 | female | 2 | 27 | 4.4 | 10 | carboplatin + paclitaxel + pembrolizumab | 6.3 | false | MSS | 2026-03-15T05:35:59.151294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432040 | REC_0009304 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 8.4 | 73 | female | 3 | 18 | 4.8 | 6 | sotorasib 960 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:59.151524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173852 | REC_0009305 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.1 | 66 | female | 1 | 15 | 6.1 | 1 | osimertinib 80 mg daily | 20.9 | false | MSI-H | 2026-03-15T05:35:59.151761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994740 | REC_0009306 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 14.9 | 68 | female | 1 | 16 | 4.9 | 7 | osimertinib 80 mg daily | 17.5 | false | MSI-H | 2026-03-15T05:35:59.151997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284167 | REC_0009307 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 27 | 8.7 | 71 | female | 1 | 16 | 5 | 0 | alectinib 600 mg BID | 28.7 | false | MSS | 2026-03-15T05:35:59.152313+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576100 | REC_0009308 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 4.7 | 66 | female | 0 | 5 | 3.6 | 7 | pembrolizumab 200 mg q3w | 8.8 | false | MSS | 2026-03-15T05:35:59.152551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481900 | REC_0009309 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 18.2 | 69 | male | 0 | 19 | 7.1 | 6 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:59.152875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192551 | REC_0009310 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 14.4 | 64 | female | 0 | 26 | 5.4 | 6 | alectinib 600 mg BID | 11.1 | false | MSI-H | 2026-03-15T05:35:59.153114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941173 | REC_0009311 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.4 | 85 | male | 3 | 30 | 7.9 | 1 | pembrolizumab 200 mg q3w | 20.9 | false | MSS | 2026-03-15T05:35:59.153355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714279 | REC_0009312 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 10.5 | 55 | female | 0 | 21 | 6 | 2 | alectinib 600 mg BID | 18.8 | true | MSI-H | 2026-03-15T05:35:59.153593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757414 | REC_0009313 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 5 | 58 | male | 1 | 15 | 5.1 | 9 | alectinib 600 mg BID | 11.4 | false | MSS | 2026-03-15T05:35:59.153826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938086 | REC_0009314 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 20.8 | 69 | male | 1 | 10 | 7.2 | 4 | sotorasib 960 mg daily | 17 | true | MSS | 2026-03-15T05:35:59.154070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150244 | REC_0009315 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 9.8 | 63 | female | 1 | 18 | 5.3 | 2 | sotorasib 960 mg daily | 4.8 | false | MSS | 2026-03-15T05:35:59.154311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256745 | REC_0009316 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 8.6 | 81 | female | 2 | 13 | 7.7 | 7 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:59.154549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451593 | REC_0009317 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 4.1 | 69 | female | 0 | 15 | 6 | 6 | pembrolizumab 200 mg q3w | 16.5 | false | MSS | 2026-03-15T05:35:59.154780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149452 | REC_0009318 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 11.1 | 63 | male | 1 | 15 | 4 | 4 | osimertinib 80 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:35:59.155019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435681 | REC_0009319 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 15.1 | 65 | female | 0 | 12 | 4.2 | 5 | entrectinib 600 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:59.155262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402384 | REC_0009320 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 12.7 | 63 | female | 1 | 20 | 6.4 | 1 | osimertinib 80 mg daily | 31.1 | false | MSI-H | 2026-03-15T05:35:59.155501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799383 | REC_0009321 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 10.4 | 61 | male | 1 | 2 | 3.4 | 1 | osimertinib 80 mg daily | 10 | false | MSI-H | 2026-03-15T05:35:59.155737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905832 | REC_0009322 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 15.3 | 69 | female | 1 | 4 | 5.4 | 2 | alectinib 600 mg BID | 18 | false | MSI-H | 2026-03-15T05:35:59.156067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987516 | REC_0009323 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 14.3 | 72 | female | 1 | 8 | 6 | 1 | alectinib 600 mg BID | 23.6 | true | MSS | 2026-03-15T05:35:59.156414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405088 | REC_0009324 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 10.3 | 59 | female | 0 | 18 | 5.9 | 0 | sotorasib 960 mg daily | 20.2 | false | MSI-H | 2026-03-15T05:35:59.156658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993439 | REC_0009325 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 9.7 | 54 | male | 0 | 17 | 5.2 | 1 | alectinib 600 mg BID | 6.5 | true | MSS | 2026-03-15T05:35:59.156896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714009 | REC_0009326 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 8.1 | 63 | female | 0 | 14 | 6.6 | 1 | pembrolizumab 200 mg q3w | 17.1 | true | MSS | 2026-03-15T05:35:59.157131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442773 | REC_0009327 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 6 | 78 | male | 1 | 19 | 5.3 | 1 | pembrolizumab 200 mg q3w | 33.4 | true | MSS | 2026-03-15T05:35:59.157374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485613 | REC_0009328 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 13.8 | 62 | male | 0 | 17 | 4.6 | 6 | osimertinib 80 mg daily | 7 | false | MSI-H | 2026-03-15T05:35:59.157618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543864 | REC_0009329 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 19 | 6 | 72 | female | 1 | 65 | 4.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 29.3 | false | MSS | 2026-03-15T05:35:59.157851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329650 | REC_0009330 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 21 | 13 | 63 | female | 1 | 21 | 6.1 | 0 | sotorasib 960 mg daily | 51 | false | MSS | 2026-03-15T05:35:59.158092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110244 | REC_0009331 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 22 | 13.8 | 78 | female | 1 | 13 | 5.6 | 0 | osimertinib 80 mg daily | 21.8 | false | MSI-H | 2026-03-15T05:35:59.158340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333943 | REC_0009332 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 10.3 | 75 | female | 2 | 14 | 5 | 5 | entrectinib 600 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:59.158583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118253 | REC_0009333 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 8.5 | 71 | female | 1 | 24 | 5 | 4 | osimertinib 80 mg daily | 15 | false | MSS | 2026-03-15T05:35:59.158816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768696 | REC_0009334 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 18.9 | 72 | male | 2 | 8 | 4.1 | 6 | sotorasib 960 mg daily | 6 | true | MSS | 2026-03-15T05:35:59.159053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228273 | REC_0009335 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 18 | 70 | female | 1 | 19 | 5.2 | 3 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.159443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576070 | REC_0009336 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.5 | 69 | female | 0 | 15 | 5.7 | 5 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:59.159679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820647 | REC_0009337 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 8.6 | 67 | female | 0 | 26 | 4.3 | 7 | entrectinib 600 mg daily | 11 | true | MSS | 2026-03-15T05:35:59.159926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448560 | REC_0009338 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 15.5 | 71 | female | 1 | 10 | 4.6 | 6 | sotorasib 960 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:59.160321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304557 | REC_0009339 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 34 | 8.9 | 60 | female | 1 | 5 | 4.7 | 1 | osimertinib 80 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:59.160571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483827 | REC_0009340 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 18.3 | 87 | male | 2 | 25 | 6.4 | 9 | osimertinib 80 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:35:59.160822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350345 | REC_0009341 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 18.8 | 56 | female | 0 | 13 | 6 | 2 | alectinib 600 mg BID | 16.4 | true | MSS | 2026-03-15T05:35:59.161071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803331 | REC_0009342 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.2 | 80 | female | 1 | 25 | 6.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.7 | false | MSS | 2026-03-15T05:35:59.161313+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475870 | REC_0009343 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.8 | 48 | female | 0 | 23 | 5.2 | 6 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:59.161563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575903 | REC_0009344 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 7.5 | 58 | male | 0 | 28 | 5.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 13.6 | false | MSS | 2026-03-15T05:35:59.161822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345715 | REC_0009345 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 9.6 | 62 | male | 0 | 62 | 4.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:35:59.162131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470518 | REC_0009346 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 11.8 | 70 | female | 3 | 13 | 4.4 | 4 | osimertinib 80 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:59.162446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705716 | REC_0009347 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 35 | 13.6 | 65 | male | 1 | 10 | 5.4 | 5 | entrectinib 600 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:59.162703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250093 | REC_0009348 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 8.8 | 76 | female | 2 | 67 | 4.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 18.5 | false | MSS | 2026-03-15T05:35:59.163077+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980258 | REC_0009349 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 8.4 | 80 | female | 0 | 10 | 4.8 | 2 | osimertinib 80 mg daily | 22.7 | false | MSS | 2026-03-15T05:35:59.163337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328604 | REC_0009350 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5.2 | 70 | male | 0 | 67 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.1 | false | MSS | 2026-03-15T05:35:59.163585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527130 | REC_0009351 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 31 | 12 | 66 | female | 0 | 17 | 5.9 | 0 | osimertinib 80 mg daily | 28.8 | true | MSI-H | 2026-03-15T05:35:59.163825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496603 | REC_0009352 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.7 | 85 | female | 2 | 7 | 5.7 | 6 | osimertinib 80 mg daily | 6.3 | false | MSS | 2026-03-15T05:35:59.164058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981434 | REC_0009353 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 18.5 | 66 | male | 0 | 12 | 7.3 | 3 | entrectinib 600 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:59.164388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816923 | REC_0009354 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 15.4 | 44 | female | 0 | 11 | 7.2 | 1 | alectinib 600 mg BID | 20.1 | true | MSS | 2026-03-15T05:35:59.164649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639185 | REC_0009355 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 17.5 | 82 | female | 1 | 17 | 6.2 | 1 | osimertinib 80 mg daily | 16.4 | true | MSI-H | 2026-03-15T05:35:59.164888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224246 | REC_0009356 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 13.6 | 64 | male | 0 | 9 | 3.8 | 2 | pembrolizumab 200 mg q3w | 15 | true | MSS | 2026-03-15T05:35:59.165139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944871 | REC_0009357 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 5.2 | 72 | female | 2 | 19 | 5 | 2 | sotorasib 960 mg daily | 31.7 | false | MSS | 2026-03-15T05:35:59.165393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379970 | REC_0009358 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 7.4 | 64 | female | 1 | 12 | 4.8 | 9 | sotorasib 960 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:59.165633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497429 | REC_0009359 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 10.9 | 51 | female | 0 | 14 | 5.3 | 4 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:59.165875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521902 | REC_0009360 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 10.2 | 61 | male | 1 | 14 | 4.7 | 0 | sotorasib 960 mg daily | 24.6 | true | MSS | 2026-03-15T05:35:59.166120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237568 | REC_0009361 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 7.5 | 70 | female | 2 | 40 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.1 | true | MSS | 2026-03-15T05:35:59.166441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967852 | REC_0009362 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 15.8 | 79 | female | 1 | 10 | 3.8 | 6 | alectinib 600 mg BID | 10.1 | true | MSI-H | 2026-03-15T05:35:59.166685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970786 | REC_0009363 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 3.8 | 81 | female | 3 | 38 | 6.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:35:59.166918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169603 | REC_0009364 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.7 | 68 | female | 0 | 55 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.5 | true | MSS | 2026-03-15T05:35:59.167162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107111 | REC_0009365 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 12.8 | 61 | male | 1 | 8 | 4 | 2 | sotorasib 960 mg daily | 23.9 | false | MSS | 2026-03-15T05:35:59.167405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935941 | REC_0009366 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 9.5 | 72 | female | 1 | 16 | 6.5 | 5 | pembrolizumab 200 mg q3w | 10.6 | false | MSS | 2026-03-15T05:35:59.167633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298737 | REC_0009367 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12 | 50 | male | 0 | 10 | 4.6 | 2 | sotorasib 960 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:59.167880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447654 | REC_0009368 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 16.3 | 77 | female | 3 | 6 | 6.1 | 2 | sotorasib 960 mg daily | 24.2 | false | MSS | 2026-03-15T05:35:59.168205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650290 | REC_0009369 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 17 | 73 | female | 1 | 17 | 6.5 | 1 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:59.168457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508690 | REC_0009370 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8.9 | 70 | male | 3 | 20 | 4.5 | 6 | alectinib 600 mg BID | 5.9 | false | MSS | 2026-03-15T05:35:59.168689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365537 | REC_0009371 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 16.7 | 62 | female | 1 | 20 | 5.3 | 0 | entrectinib 600 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:59.168934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932140 | REC_0009372 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 9.1 | 77 | female | 1 | 61 | 6.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.3 | false | MSS | 2026-03-15T05:35:59.169177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588066 | REC_0009373 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5.6 | 66 | male | 1 | 49 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:35:59.169418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802884 | REC_0009374 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 18.1 | 76 | female | 2 | 11 | 5.6 | 2 | alectinib 600 mg BID | 16.3 | false | MSI-H | 2026-03-15T05:35:59.169750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942650 | REC_0009375 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8.8 | 70 | female | 1 | 25 | 4.6 | 5 | alectinib 600 mg BID | 18.5 | false | MSS | 2026-03-15T05:35:59.170002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460514 | REC_0009376 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.1 | 70 | female | 3 | 52 | 4.7 | 6 | pembrolizumab 200 mg q3w | 15.1 | true | MSS | 2026-03-15T05:35:59.170249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903094 | REC_0009377 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13.2 | 74 | female | 1 | 14 | 4.8 | 2 | entrectinib 600 mg daily | 32.3 | true | MSI-H | 2026-03-15T05:35:59.170493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835232 | REC_0009378 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 8.1 | 62 | female | 0 | 13 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.1 | true | MSS | 2026-03-15T05:35:59.170741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249012 | REC_0009379 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.3 | 58 | male | 0 | 41 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.1 | false | MSS | 2026-03-15T05:35:59.170996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354847 | REC_0009380 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 6.8 | 47 | male | 0 | 0 | 2.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.4 | false | MSS | 2026-03-15T05:35:59.171232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878155 | REC_0009381 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 7.5 | 80 | female | 2 | 16 | 4.6 | 5 | osimertinib 80 mg daily | 18 | false | MSS | 2026-03-15T05:35:59.171464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812015 | REC_0009382 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 20 | 11.8 | 53 | male | 0 | 15 | 6.2 | 0 | osimertinib 80 mg daily | 49.9 | true | MSI-H | 2026-03-15T05:35:59.171699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991777 | REC_0009383 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15 | 71 | female | 1 | 9 | 6.1 | 5 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:59.171939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371696 | REC_0009384 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 5.8 | 75 | female | 3 | 3 | 3.4 | 4 | entrectinib 600 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:59.172219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472259 | REC_0009385 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 13.7 | 55 | male | 1 | 13 | 4.5 | 6 | sotorasib 960 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:35:59.172479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457025 | REC_0009386 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13.7 | 68 | male | 0 | 6 | 6.7 | 2 | entrectinib 600 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:59.172732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279263 | REC_0009387 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 16.3 | 73 | female | 1 | 11 | 6.2 | 2 | entrectinib 600 mg daily | 18.2 | true | MSI-H | 2026-03-15T05:35:59.173067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332034 | REC_0009388 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.1 | 66 | female | 0 | 13 | 3.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:35:59.173313+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756384 | REC_0009389 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.9 | 68 | female | 1 | 26 | 3.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.8 | false | MSS | 2026-03-15T05:35:59.173555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678726 | REC_0009390 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 9.6 | 72 | female | 2 | 5 | 5.8 | 5 | entrectinib 600 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:59.173804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587860 | REC_0009391 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 12.8 | 56 | male | 1 | 18 | 7 | 2 | alectinib 600 mg BID | 23.7 | true | MSI-H | 2026-03-15T05:35:59.174057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681333 | REC_0009392 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 17.1 | 70 | female | 2 | 11 | 7.4 | 1 | osimertinib 80 mg daily | 30.9 | false | MSS | 2026-03-15T05:35:59.174307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702270 | REC_0009393 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 8.6 | 69 | female | 1 | 14 | 6.1 | 2 | alectinib 600 mg BID | 17.3 | true | MSS | 2026-03-15T05:35:59.174550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169566 | REC_0009394 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4 | 66 | female | 0 | 55 | 6.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.8 | false | MSS | 2026-03-15T05:35:59.174783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233050 | REC_0009395 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 4.8 | 62 | female | 0 | 33 | 7.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.2 | false | MSS | 2026-03-15T05:35:59.175026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237215 | REC_0009396 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 9.5 | 65 | female | 1 | 6 | 6.4 | 4 | sotorasib 960 mg daily | 14.7 | true | MSS | 2026-03-15T05:35:59.175269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643037 | REC_0009397 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 4.3 | 73 | female | 1 | 16 | 5.3 | 1 | osimertinib 80 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:59.175507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519557 | REC_0009398 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 14.7 | 78 | female | 1 | 19 | 3.7 | 6 | pembrolizumab 200 mg q3w | 17.1 | false | MSI-H | 2026-03-15T05:35:59.175751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733295 | REC_0009399 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.7 | 76 | male | 2 | 17 | 3.4 | 5 | alectinib 600 mg BID | 15.4 | false | MSI-H | 2026-03-15T05:35:59.176000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149301 | REC_0009400 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 16.7 | 61 | female | 0 | 10 | 2.9 | 4 | entrectinib 600 mg daily | 12 | true | MSS | 2026-03-15T05:35:59.176493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.